
|Videos|January 13, 2014
The Utility of TH-302 in Sarcoma
Author(s)Vicki Keedy, MD
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.
Advertisement
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.
Clinical Pearls:
- TH-302 is similar to ifosfamide but is a hypoxia-induced agent
- TH-302 targets the large areas of hypoxia found in sarcomas that chemotherapy cannot reach
- A randomized phase III study of Adriamycin (doxorubicin) versus Adriamycin plus TH-302 is undergoing accrual
- The initial phase II data is promising with good progression-free survival data
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5







































